NCT07775833

Brief Summary

The investigator's objective is to explore the definitive evidence of mushroom on cognitive functions among at-risk middle-aged and young-olds. The investigator carefully designed a randomized controlled trial (RCT) to assess the role of mushrooms in promoting cognitive functioning among around 600 middle-aged adults and young-olds. Participants were selected based on specific inclusion criteria, such as being community-living adults aged 45-80 years with a family history of dementia or subjective cognitive decline, while consuming mushrooms no more than once a week and having no dementia, along with the exclusion of individuals with neurological or psychiatric disorders and significant sensory or motor impairments. Participants in the intervention group will consume Pleurotus citrinopileatus mushroom powder daily for 24months, with compliance

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
600

participants targeted

Target at P75+ for not_applicable

Timeline
51mo left

Started Oct 2026

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 21, 2026

Completed
1 month until next milestone

First Posted

Study publicly available on registry

August 20, 2026

Completed
1 month until next milestone

Study Start

First participant enrolled

October 1, 2026

Completed
2.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2028

Expected
2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2030

Last Updated

September 1, 2026

Status Verified

April 1, 2026

Enrollment Period

2.2 years

First QC Date

July 21, 2026

Last Update Submit

August 28, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • MMSE

    Total scores change

    24 months

Secondary Outcomes (7)

  • plasma ergothioneine

    24 months

  • Rey Auditory Verbal Learning Test

    12, and 24 months

  • inflammatory markers

    24 months

  • NfL

    24 months

  • Epigenetic age

    24 months

  • +2 more secondary outcomes

Study Arms (2)

mushroom powder intervention arm

EXPERIMENTAL
Dietary Supplement: Golden oyster mushroom powder

Placebo arm

NO INTERVENTION

Interventions

Participants in the intervention group will consume Pleurotus citrinopileatus mushroom powder daily for 24months, with compliance monitored using electronic diary apps. The powder contains 7.0 mg/g of ergothioneine (dry weight).

mushroom powder intervention arm

Eligibility Criteria

Age45 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • (1) Community-living adult aged 45 years to 80 years, AND
  • (2) Family history of Alzheimer's disease or having subjective cognitive (SCD) defined as "self-reported memory problems that have been getting worse over the past year.", AND
  • (3) Consume mushrooms no more than once a week, AND
  • (4) No dementia: CDR global score equal to zero.

You may not qualify if:

  • (1) Any diagnosis of neurological diseases (e.g., epilepsy, stroke) made by a clinician, OR
  • (2) Any diagnosis of psychiatric illnesses (e.g., depressive disorders) made by a clinician, OR
  • (3) Significant sensory or motor impairments, OR
  • (4) Known allergy to mushrooms or a history of serious food allergies, OR
  • (5) Participants with a history of gout, OR
  • (6) Diagnosed with hyperuricemia.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Tahir Foundation Building, MD1, Level 12 (12 Science Drive 2)

Singapore, 117549, Singapore

RECRUITING

MeSH Terms

Conditions

Dementia

Condition Hierarchy (Ancestors)

Brain DiseasesCentral Nervous System DiseasesNervous System DiseasesNeurocognitive DisordersMental Disorders

Study Officials

  • Lei FEng

    National University of Singapore

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

July 21, 2026

First Posted

August 20, 2026

Study Start

October 1, 2026

Primary Completion (Estimated)

December 1, 2028

Study Completion (Estimated)

December 1, 2030

Last Updated

September 1, 2026

Record last verified: 2026-04

Locations